An inflammatory factor may be important in the development of aortic stenosis and anti-inflammatory medication could be a possible new treatment.
A specific inflammatory factor may be important in the development of aortic stenosis. The results suggest that anti-inflammatory medication could be a possible new treatment, according to research from the Karolinska Institutet.
Aortic stenosis is typically seen in the elderly, but can also be caused by a congenital defect. Aortic stenosis is currently treated by surgical replacement of the diseased valve, but research is ongoing to identify drugs that can delay the progress of the disease.
In a new study presented in the journal Circulation, researchers from the institute show that specific pathways of inflammation are important underlying factors in the development of aortic stenosis.
By studying heart valves from patients undergoing surgery for various valve diseases, the researchers have shown that immune cells and a group of inflammatory substances called leukotrienes can be found in calcified heart valves.
The most significant inflammation was seen in patients with the narrowest valves on ultrasound examination. The researchers have also shown in cell cultures that leukotrienes stimulate the calcification of heart valve cells.
There are similarities between atherosclerosis and aortic stenosis. However, statins, which are capable of preventing atherosclerosis, have proved ineffective in preventing calcification of the aortic valve.
“The results suggest that anti-inflammatory medication could be a future treatment for aortic stenosis, and it would mean a lot to these patients, most of whom are elderly, if we could slow the disease to the extent that they do not need surgery,” associate professor and cardiologist Magnus Bäck, MD, one of the researchers involved in the study, said in a statement.